Every 8-K that Edwards Lifesciences Corp (EW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EW filings page.
Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027. The board will begin a selection process promptly to identify a successor, with a transition of duties expected during 2027.
The company also states that Mr. Bobo is expected to remain with Edwards as a consultant through the end of 2027, providing continuity during and after the leadership transition.
Edwards Lifesciences reported strong second quarter 2026 results, with net sales of $1.74 billion, up 13.6% year over year (constant currency growth 12.5%). Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.26 billion, up 11.3%, Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were $195.9 million, up 47.3%, and Surgical sales were $284.1 million, up 6.5%. GAAP diluted EPS was $0.42, while adjusted EPS was $0.78. Gross margin was 77.5% and operating margin 29.5% (30.0% adjusted).
Results included a $40.0 million impairment charge and a $188.2 million valuation allowance tied to a California R&D tax credit law change, driving an effective tax rate of 53.6% and lower GAAP EPS versus $0.57 a year earlier. Cash and cash equivalents were about $2.9 billion, with total debt near $600 million and $1.5 billion remaining under the share repurchase authorization.
Based on this performance, Edwards raised 2026 constant currency sales growth guidance to 10%–11%, TAVR growth to 8%–9%, and TMTT sales guidance to $760–$780 million, now expecting total 2026 sales of $6.6–$6.9 billion and TAVR sales of $4.75–$5.0 billion. Adjusted EPS guidance of $2.95–$3.05 was reaffirmed. For Q3 2026, projected sales are $1.63–$1.71 billion, with adjusted EPS of $0.71–$0.77.
Edwards Lifesciences Corporation reported results from its 2026 annual stockholders meeting. Stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program, increasing the total shares of common stock available under the plan by 7,000,000 to 341,500,000 shares.
All director nominees were elected with strong majorities, and stockholders approved the advisory vote on named executive officer compensation. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the amended and restated long-term stock incentive program.
Edwards Lifesciences Corporation filed a Form 8-K announcing that Theodora (“Doretta”) Mistras has been appointed Corporate Vice President and Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem. The company highlights her prior experience as CFO of Viatris and senior roles in healthcare investment banking.
Under her offer letter, Mistras will receive a base salary of $925,000, a target annual bonus of at least 100% of base salary under the Edwards Lifesciences Incentive Plan, and a $2,013,000 sign-on bonus subject to pro-rata repayment if she departs within 24 months in certain circumstances. She will also receive $8,000,000 in restricted stock units vesting over three years, an initial 2026 annual equity award valued at $4,500,000, severance protections of at least one times salary and target bonus plus a pro-rated bonus and $50,000 in outplacement benefits, and reimbursement of up to $15,000 in legal fees and relocation costs.
Edwards Lifesciences reported strong first quarter 2026 results, with net sales of $1.65 billion, up 16.7% year over year, and constant currency sales growth of 12.7%. GAAP diluted EPS was $0.66 and adjusted EPS was $0.78, reflecting solid operational performance.
TAVR sales rose 14.4% to $1.20 billion and TMTT sales reached $173 million, both supported by broader adoption of SAPIEN, EVOQUE, PASCAL and SAPIEN M3 therapies. Surgical sales grew 10.1% to $276 million, driven by RESILIA-based products and new launches.
The company raised its 2026 constant currency sales growth guidance to 9%–11%, TAVR growth guidance to 7%–9%, and adjusted EPS guidance to $2.95–$3.05. Gross margin remained high at 78.0% (78.2% adjusted). Edwards ended the quarter with about $2.4 billion in cash, $600 million of total debt, and completed a $500 million accelerated share repurchase.
Edwards Lifesciences reported strong growth for the quarter and year ended Dec. 31, 2025, while GAAP earnings were pressured by large one‑time charges. Q4 net sales rose 13.3% to $1.57 billion, led by Transcatheter Aortic Valve Replacement (TAVR) sales of $1.16 billion, up 12.0%, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $156 million, which grew more than 40%.
Q4 diluted EPS from continuing operations was $0.11, while adjusted EPS was $0.58, reflecting exclusions such as $208.6 million of certain litigation expenses and a $99.8 million loss on impairment in the quarter. Full‑year 2025 net sales increased 11.5% to $6.07 billion, with TAVR and TMTT both delivering double‑digit constant‑currency growth.
The company guided to 2026 constant‑currency sales growth of 8–10% and expects TMTT revenue of $740–$780 million, implying 35–45% growth. Edwards also targets 2026 adjusted EPS of $2.90–$3.05 and an adjusted operating margin at the high end of a 28–29% range, supported by a broad structural heart portfolio and multiple product and clinical trial catalysts.
Edwards Lifesciences Corporation reports that the United States District Court for the District of Columbia has granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc. As a direct result of this court action, Edwards states that it will not acquire JenaValve.
The update is presented as an other event and is based on a company press release dated January 9, 2026, which is attached as an exhibit. The filing focuses on the legal outcome affecting this specific transaction and does not provide additional financial figures or broader business updates.
Edwards Lifesciences announced a planned leadership change as Chief Financial Officer Scott Ullem informed the company he will transition from his role by mid-year 2026.
The company has begun a selection process to appoint a new CFO. A press release announcing the transition plan was issued on October 30, 2025 and furnished under Item 7.01; it is not deemed “filed” under the Exchange Act.
Edwards Lifesciences (EW) furnished a press release announcing its financial results for the third quarter of 2025. The disclosure was made via Form 8-K under Item 2.02.
The press release is included as Exhibit 99.1 and the information is being furnished, not deemed filed, under the Exchange Act.
Edwards Lifesciences Corporation reported that on August 19, 2025 it issued a press release announcing that the company entered into an accelerated share repurchase agreement. This type of agreement typically allows a company to buy back a significant number of its shares more quickly than through open-market repurchases, which can affect earnings per share and overall capital structure.
The press release describing the accelerated share repurchase is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms and conditions are contained in that accompanying document rather than in this report.